002405SZSE

2025 Annual Report of Independent Director (Wang Xiao)

SeeWay.ai Co., Ltd.·

✨ AI Summary

This report details the independent director's performance in 2025, focusing on attendance at meetings, review of proposals, and safeguarding shareholder interests. The director actively participated in board and committee meetings, reviewed financial reports, and ensured compliance with regulations. Key decisions involved related-party transactions and the reappointment of auditors. The director's overall performance is evaluated positively, with a commitment to continued diligence in 2026.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Beijing Wintime Technology Co., Ltd. 2025 Annual Report of Independent Director (Wang Xiao)

As an independent director of Beijing Wintime Technology Co., Ltd. (hereinafter referred to as the "Company"), in accordance with the "Company Law," "Administrative Measures for Independent Directors of Listed Companies," "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 1 - Normative Operation of Main Board Listed Companies," and the "Articles of Association," "Work System for Independent Directors," and "Work System for Special Meetings of Independent Directors," and other relevant laws and regulations, I have faithfully performed my duties as an independent director, actively attended relevant meetings of the Company in 2025, carefully reviewed all proposals, and protected the overall interests of the Company and the interests of all shareholders, especially minority shareholders. The performance of my duties as an independent director in 2025 is reported as follows:

I. Basic Information of the Independent Director

Wang Xiao, Chinese national, no overseas residency, born in January 1975, holds a Ph.D. in Management, is a Certified Public Accountant in China, a Chartered Financial Analyst (CFA), and a professor (part-time) at the Academy of Actuarial Science, Central University of Finance and Economics. He currently serves as an independent director of the Company. He has previously served as a member of the Executive Committee and Deputy General Manager of Lufax at Ping An Group, Partner at IDG Capital, Partner at Hillhouse Capital, Managing Director and Investment Committee Member at CPE Yuanfeng, and Vice President of China Biopharmaceutical.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.